← Leaderboards
Ofer Levy
Brigham And Women'S Hospital
$23,792,522
Attributed
$23,792,522
Total exposure
19
Grants
18
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $14.4M · FY2005–25$20M$15M$10M$5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$54,777,042 · 21
By mechanism
U19$43,945,967 · 13
R01$4,543,329 · 2
U01$2,891,807 · 1
N01$2,547,484 · 1
K08$490,806 · 1
P51$357,649 · 3
Top collaborators
No co-investigators on record.
Most similar at Brigham And Women'S Hospital
Same institution · by research overlap
- Michael R Wessels$15,732,288
- Anushua Sinha$705,325
- Lawrence C. Madoff$1,764,015
- Richard Malley$13,476,616
- Karen M Puopolo$682,871
Others in their field
Top investigators on “Immune Response”
- Lawrence Corey · Fred Hutchinson Cancer Center$680,290,567
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$542,695,345
- Barton F Haynes · Duke University$456,664,915
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$342,310,423
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$309,708,725
- Peter B. Gilbert · Fred Hutchinson Cancer Center$192,329,665
Research focus
Immune ResponseVaccinesInfectionNewborn InfantLifeCellsResponseIn VitroImmuneBiological MarkersMediatingSystems BiologyMolecularSamplingNeonatalInsightVaccine ResponseInfantCohortImmunogenicityPlasmaAdultProteomicsImmunization
Grant awards (74)
Immune development in early life (IDEAL) shapes vaccine response, respiratory infectious diseaseand asthma$1,534,027
U19 · FY2025 · AI · contact PI
VACCINE ADJUVANT DISCOVERY PROGRAM (VADP)$1,112,104
N01 · FY2025 · AI · contact PI
Administrative Core: IDEAL shapes vaccine response, susceptibility to respiratory infectious disease and asthma$191,754
U19 · FY2025 · AI · contact PI
Project 3: In vitro modeling to define mechanisms of childhood vaccine response, susceptibility to respiratory infectious disease and asthma$191,753
U19 · FY2025 · AI · contact PI
Immune development in early life (IDEAL) shapes vaccine response, respiratory infectious diseaseand asthma$1,542,768
U19 · FY2024 · AI · contact PI
VACCINE ADJUVANT DISCOVERY PROGRAM (VADP)$1,435,380
N01 · FY2024 · AI · contact PI
Administrative Core: IDEAL shapes vaccine response, susceptibility to respiratory infectious disease and asthma$199,833
U19 · FY2024 · AI · contact PI
Project 3: In vitro modeling to define mechanisms of childhood vaccine response, susceptibility to respiratory infectious disease and asthma$161,681
U19 · FY2024 · AI · contact PI
Immune development in early life (IDEAL) shapes vaccine response, respiratory infectious diseaseand asthma$1,546,537
U19 · FY2023 · AI · contact PI
Project 3: In vitro modeling to define mechanisms of childhood vaccine response, susceptibility to respiratory infectious disease and asthma$227,924
U19 · FY2023 · AI · contact PI
Administrative Core: IDEAL shapes vaccine response, susceptibility to respiratory infectious disease and asthma$111,757
U19 · FY2023 · AI · contact PI
Immune development in early life (IDEAL) shapes vaccine response, respiratory infectious diseaseand asthma$1,665,877
U19 · FY2022 · AI · contact PI
Project 3: In vitro modeling to define mechanisms of childhood vaccine response, susceptibility to respiratory infectious disease and asthma$198,606
U19 · FY2022 · AI · contact PI
Administrative Core: IDEAL shapes vaccine response, susceptibility to respiratory infectious disease and asthma$123,900
U19 · FY2022 · AI · contact PI
Systems Biology to Identify Biomarkers of Neonatal Vaccine Immunogenicity$2,275,700
U19 · FY2021 · AI · contact PI
IMPACC convalescent data collection, including Patient Reported Outcomes (PROs) and home visit sampling$2,129,888
U19 · FY2021 · AI · contact PI
Systems Biology to Identify Biomarkers of Neonatal Vaccine Immunogenicity$2,102,997
U19 · FY2021 · AI · contact PI
Clinical and Data Coordinating Center (CDCC)]$2,102,997
U19 · FY2021 · AI · contact PI
Systems Biology to Identify Biomarkers of Neonatal Vaccine Immunogenicity$2,076,274
U19 · FY2021 · AI · contact PI
In vitro modeling to characterize mechanisms of neonatal vaccine induced immune responses$855,154
U19 · FY2021 · AI · contact PI
Systems Biology to Identify Biomarkers of Neonatal Vaccine Immunogenicity$855,154
U19 · FY2021 · AI · contact PI
IMPACC convalescent data collection, including Patient Reported Outcomes (PROs) and home visit sampling$800,481
U19 · FY2021 · AI · contact PI
In vitro modeling to characterize mechanisms of neonatal vaccine induced immune responses$384,734
U19 · FY2021 · AI · contact PI
Newborn cohorts to discover and validate biomarkers of neonatal vaccine immunogenicity$311,186
U19 · FY2021 · AI · contact PI
Systems Biology to Identify Biomarkers of Neonatal Vaccine Immunogenicity$161,484
U19 · FY2021 · AI · contact PI
Newborn cohorts to discover and validate biomarkers of neonatal vaccine immunogenicity$161,484
U19 · FY2021 · AI · contact PI
Administrative Core: Systems Biology to Identify Biomarkers of Neonatal Vaccine Immunogenicity$138,222
U19 · FY2021 · AI · contact PI
IMmunoPhenotyping Assessment in a COVID-19 Cohort (IMPACC): Clinical and Data Coordinating Center (CDCC)$2,426,447
U19 · FY2020 · AI · contact PI
Clinical and Data Coordinating Center (CDCC)]$2,426,447
U19 · FY2020 · AI · contact PI
COVID-19 Immunophenotyping Proteomics and Metabolomics Core (PMC)$2,174,014
U19 · FY2020 · AI · contact PI
Systems Biology to Identify Biomarkers of Neonatal Vaccine Immunogenicity$2,057,593
U19 · FY2020 · AI · contact PI
Newborn cohorts to discover and validate biomarkers of neonatal vaccine immunogenicity$558,074
U19 · FY2020 · AI · contact PI
Dissecting the mechanism of age-specific adjuvant synergy in vitro and in vivo$537,172
U01 · FY2020 · AI · contact PI
In vitro modeling to characterize mechanisms of neonatal vaccine induced immune responses$446,762
U19 · FY2020 · AI · contact PI
In vitro modeling to characterize mechanisms of neonatal vaccine induced immune responses$308,143
U19 · FY2020 · AI · contact PI
IMmunoPhenotyping Assessment of a Covid-19 Cohort (IMPACC): Immunophenotyping of innate and adaptive immune response to SARS-CoV-2 infection.$308,143
U19 · FY2020 · AI · contact PI
IMmunoPhenotyping Assessment of a Covid-19 Cohort (IMPACC): Clinical Site$184,957
U19 · FY2020 · AI · contact PI
Newborn cohorts to discover and validate biomarkers of neonatal vaccine immunogenicity$184,957
U19 · FY2020 · AI · contact PI
Administrative Core: Systems Biology to Identify Biomarkers of Neonatal Vaccine Immunogenicity$111,164
U19 · FY2020 · AI · contact PI
Systems Biology to Identify Biomarkers of Neonatal Vaccine Immunogenicity$111,094
U19 · FY2020 · AI · contact PI
Systems Biology to Identify Biomarkers of Neonatal Vaccine Immunogenicity$1,984,196
U19 · FY2019 · AI · contact PI
Newborn cohorts to discover and validate biomarkers of neonatal vaccine immunogenicity$910,412
U19 · FY2019 · AI · contact PI
Dissecting the mechanism of age-specific adjuvant synergy in vitro and in vivo$556,516
U01 · FY2019 · AI · contact PI
In vitro modeling to characterize mechanisms of neonatal vaccine induced immune responses$234,120
U19 · FY2019 · AI · contact PI
Administrative Core: Systems Biology to Identify Biomarkers of Neonatal Vaccine Immunogenicity$99,108
U19 · FY2019 · AI · contact PI
Systems Biology to Identify Biomarkers of Neonatal Vaccine Immunogenicity$3,018,569
U19 · FY2018 · AI · contact PI
Newborn cohorts to discover and validate biomarkers of neonatal vaccine immunogenicity$1,007,530
U19 · FY2018 · AI · contact PI
Dissecting the mechanism of age-specific adjuvant synergy in vitro and in vivo$534,030
U01 · FY2018 · AI · contact PI
In vitro modeling to characterize mechanisms of neonatal vaccine induced immune responses$164,146
U19 · FY2018 · AI · contact PI
Administrative Core: Systems Biology to Identify Biomarkers of Neonatal Vaccine Immunogenicity$104,005
U19 · FY2018 · AI · contact PI
Systems Biology to Identify Biomarkers of Neonatal Vaccine Immunogenicity$2,028,320
U19 · FY2017 · AI · contact PI
Newborn cohorts to discover and validate biomarkers of neonatal vaccine immunogenicity$718,534
U19 · FY2017 · AI · contact PI
Dissecting the mechanism of age-specific adjuvant synergy in vitro and in vivo$708,066
U01 · FY2017 · AI · contact PI
In vitro modeling to characterize mechanisms of neonatal vaccine induced immune responses$190,972
U19 · FY2017 · AI · contact PI
Administrative Core: Systems Biology to Identify Biomarkers of Neonatal Vaccine Immunogenicity$136,088
U19 · FY2017 · AI · contact PI
Dissecting the mechanism of age-specific adjuvant synergy in vitro and in vivo$556,023
U01 · FY2016 · AI · contact PI
Modeling distinct neonatal purine metabolism to inform vaccine development$442,500
R01 · FY2016 · AI · contact PI
Modeling distinct neonatal purine metabolism to inform vaccine development$631,581
R01 · FY2015 · AI · contact PI
Modeling distinct neonatal purine metabolism to inform vaccine development$534,907
R01 · FY2014 · AI · contact PI
Modeling distinct neonatal purine metabolism to inform vaccine development$426,300
R01 · FY2013 · AI · contact PI
Modeling distinct neonatal purine metabolism to inform vaccine development$435,000
R01 · FY2012 · AI · contact PI
Adenosine Shapes Neonatal Toll-like Receptor Function$358,586
R01 · FY2010 · AI · contact PI
Adenosine Shapes Neonatal Toll-like Receptor Function$240,566
R01 · FY2010 · AI · contact PI
Adenosine Shapes Neonatal Toll-like Receptor Function$362,208
R01 · FY2009 · AI · contact PI
NEONATAL VACCINE ADJUVANT POTENTIAL OF TOLL-LIKE RECEPTOR 8 AGONISTS$111,945
P51 · FY2009 · RR · contact PI
Adenosine Shapes Neonatal Toll-like Receptor Function$362,208
R01 · FY2008 · AI · contact PI
NEONATAL VACCINE ADJUVANT POTENTIAL OF TOLL-LIKE RECEPTOR 8 AGONISTS$55,151
P51 · FY2008 · RR · contact PI
Adenosine Shapes Neonatal Toll-like Receptor Function$369,223
R01 · FY2007 · AI · contact PI
NEONATAL VACCINE ADJUVANT POTENTIAL OF TOLL-LIKE RECEPTOR 8 AGONISTS$190,553
P51 · FY2007 · RR · contact PI
Adenosine Shapes Neonatal Toll-like Receptor Function$380,250
R01 · FY2006 · AI · contact PI
Determinants of Innate Immunity to Group B Streptococci$122,283
K08 · FY2005 · AI
Determinants of Innate Immunity to Group B Streptococci$122,283
K08 · FY2004 · AI
Determinants of Innate Immunity to Group B Streptococci$128,520
K08 · FY2003 · AI
Determinants of Innate Immunity to Group B Streptococci$117,720
K08 · FY2002 · AI